Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide that has attracted significant scientific interest across multiple research disciplines. First isolated from porcine intestinal tissue in 1970, VIP peptide research has since expanded to explore its roles in neuroimmune signaling, smooth muscle biology, and circadian rhythm regulation. Its broad receptor expression and multi-system activity make it one of the most studied endogenous neuropeptides in preclinical science.
Research into VIP has accelerated considerably in recent years, with preclinical models investigating its interactions with VPAC1 and VPAC2 receptors across neurological, pulmonary, and gastrointestinal tissue systems. This guide consolidates the current state of VIP peptide research, covering receptor biology, proposed mechanisms of action, and the range of preclinical study findings published through 2026.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied.
VIP - 10MG — Research-Grade Reference Material VIP - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Glutathione 1500MG
$85.00$63.75 with 1st order
Epithalon - 10MG
$50.00$37.50 with 1st order
DSIP - 10MG
$70.00$52.50 with 1st order
P21 - 10MG
$85.00$63.75 with 1st order
Frequently Asked Questions
What is VIP peptide and where is it found in the body?
Vasoactive intestinal peptide (VIP) is a 28-amino acid neuropeptide endogenously expressed throughout the central nervous system, gastrointestinal tract, respiratory system, and immune tissue. It functions as both a neurotransmitter and a neuromodulator, with preclinical studies identifying VIP-positive neurons in the hypothalamus, cortex, and enteric nervous system.
What receptors does VIP bind to in preclinical research models?
VIP exerts its effects primarily through two G protein-coupled receptors: VPAC1 and VPAC2. Both receptors are positively coupled to adenylate cyclase via Gs proteins, triggering cAMP-dependent signaling cascades. VPAC1 is broadly expressed across numerous tissue types, while VPAC2 shows higher selectivity for smooth muscle and immune cell populations in preclinical models.
What has preclinical research found about VIP and immune system biology?
Preclinical studies have explored VIP’s modulatory interactions with immune cell populations including T lymphocytes, macrophages, and dendritic cells. Research suggests VIP signaling through VPAC receptors may influence cytokine expression profiles and T-cell differentiation patterns in in vitro and rodent models, making it a subject of active neuroimmunology research.
Has VIP peptide been studied in relation to circadian rhythm biology?
Yes. Preclinical research has extensively examined VIP’s role in the suprachiasmatic nucleus (SCN), the brain’s primary circadian pacemaker. Studies in rodent models have found that VIP and its VPAC2 receptor appear to be involved in synchronizing circadian oscillators across SCN neurons, with VIP-deficient models showing disrupted circadian rhythm patterns in multiple parameters.
What is the difference between VIP and secretin in research contexts?
VIP and secretin are structurally related members of the glucagon superfamily of peptides. Both activate overlapping receptor systems, but VIP exhibits broader tissue distribution and more diverse neuromodulatory activity in preclinical models. Secretin research has been more narrowly focused on pancreatic and biliary secretion biology, while VIP research spans neurological, immune, and gastrointestinal systems.
What in vitro models have been used to study VIP peptide mechanisms?
Researchers have employed a range of in vitro systems including primary neuronal cultures, intestinal epithelial cell lines, pulmonary smooth muscle preparations, and peripheral blood mononuclear cell (PBMC) assays. These models have been used to characterize receptor binding kinetics, downstream cAMP signaling, and gene expression changes associated with VIP receptor activation.
Is VIP peptide stable for laboratory research use?
VIP is a relatively fragile peptide in aqueous solution and is susceptible to enzymatic degradation by neutral endopeptidase and dipeptidyl peptidase IV in biological matrices. Laboratory handling protocols typically involve cold storage, lyophilized formulation prior to use, and careful reconstitution procedures to preserve peptide integrity during research applications.
Where can researchers source VIP peptide for laboratory studies?
VIP peptide is available as a lyophilized research material through specialized peptide suppliers. Source Peptides offers VIP in a 10MG research format for qualified laboratory use, available with appropriate reconstitution materials for in vitro and preclinical study applications.
VIP Peptide Structure and Endogenous Biology
Vasoactive intestinal peptide belongs to the secretin/glucagon superfamily of peptides, sharing structural homology with pituitary adenylate cyclase-activating polypeptide (PACAP), secretin, and glucagon. The 28-amino acid sequence of VIP contains an N-terminal histidine residue critical for receptor recognition — a structural feature conserved across this peptide superfamily and necessary for full biological activity at VPAC receptors.
VIP - 10MG — Research-Grade Reference Material VIP - 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Glutathione 1500MG
$85.00$63.75 with 1st order
Epithalon - 10MG
$50.00$37.50 with 1st order
DSIP - 10MG
$70.00$52.50 with 1st order
P21 - 10MG
$85.00$63.75 with 1st order
VIP is encoded by the VIP gene, which also encodes the related peptide PHM (peptide histidine methionine) through alternative post-translational processing. In preclinical models, VIP-expressing neurons have been identified across a remarkably broad range of tissues, including the hypothalamus, neocortex, hippocampus, retina, enteric nervous system, bronchial epithelium, and various immune organs. This widespread distribution has contributed to VIP’s emergence as a key subject in neuroimmune and systems biology research.
As noted in MOTS-C peptide research, mitochondrial-derived signaling peptides often demonstrate similarly broad multi-tissue activity — a pattern increasingly recognized across diverse classes of bioactive peptides in current preclinical science.
VPAC1 and VPAC2 Receptor Biology
VIP’s biological activity in preclinical models is mediated almost exclusively through two class B G protein-coupled receptors (GPCRs): VPAC1 (also designated VIPR1) and VPAC2 (VIPR2). Both receptors couple to Gs proteins and activate adenylate cyclase upon VIP binding, producing intracellular cAMP elevations that drive downstream PKA-dependent signaling cascades. Some preclinical studies have also reported VPAC receptor-associated activation of phospholipase C and calcium mobilization, suggesting coupling to additional G protein subtypes under certain conditions.
VPAC1 Receptor Distribution
VPAC1 is broadly expressed and has been identified in intestinal epithelium, lung tissue, liver, lymphocytes, and regions of the central nervous system in preclinical models. Binding affinity studies have shown that VIP and PACAP-27 exhibit comparable affinity for VPAC1, while the longer PACAP-38 isoform exhibits somewhat lower selectivity. Research using VPAC1 knockout rodent models has helped clarify the receptor’s contributions to intestinal secretomotor function and immune cell regulation.
VPAC2 Receptor Distribution
VPAC2 shows a more selective expression profile, with high levels documented in the suprachiasmatic nucleus, pancreatic islets, smooth muscle, cardiac tissue, and T lymphocyte subpopulations in preclinical models. VPAC2 is distinguished from VPAC1 by its higher selectivity for PACAP and by pharmacological tools such as the selective agonist Ro 25-1553, which has been used in receptor-specific research protocols to dissect VPAC2-mediated signaling.
VIP 10MG for laboratory research →
Preclinical Research Areas: Key Findings
Neuroimmune Signaling Research
One of the most extensively studied aspects of VIP biology involves its interactions with immune cell populations. Preclinical in vitro studies have demonstrated that VIP can influence the production of pro-inflammatory and anti-inflammatory cytokines in macrophage and dendritic cell models. Research published across multiple laboratory groups has explored VIP’s apparent ability to modulate Th1/Th2 cytokine balance in T lymphocyte cultures, with findings suggesting VPAC receptor signaling may shift cytokine expression profiles in ways that researchers have characterized as relevant to neuroimmune crosstalk models.
Rodent models have also been employed to examine VIP’s interaction with mast cells, which co-localize with VIP-positive nerve fibers in intestinal and pulmonary tissue. These studies form part of a broader investigation into how neuropeptides coordinate immune surveillance at mucosal interfaces — a research area with significant overlap with TB-500’s tissue remodeling research in mucosal and connective tissue contexts.
Circadian Rhythm and SCN Biology
Among VIP’s most well-characterized preclinical roles is its involvement in suprachiasmatic nucleus (SCN) function. The SCN, located in the hypothalamus, serves as the master circadian pacemaker in mammals. Preclinical studies using VIP-null and VPAC2-null rodent models have consistently demonstrated disrupted circadian locomotor activity rhythms, reduced amplitude of molecular clock oscillations, and desynchronization of individual SCN neurons compared to wild-type controls.
Research has proposed that VIP released from SCN neurons acts as a synchronizing signal, entraining neighboring neurons to maintain coherent circadian rhythm outputs. This paracrine signaling model has been supported by electrophysiological recordings in SCN slice preparations, where VIP application was observed to phase-shift spontaneous firing rate rhythms in a time-dependent manner in preclinical laboratory preparations.
Pulmonary and Airway Biology
VIP was originally named in part for its potent vasodilatory properties observed in early bioassay preparations, and preclinical pulmonary research has continued to investigate its role in airway smooth muscle biology. In vitro studies using isolated bronchial smooth muscle preparations have characterized VIP’s relaxant properties through cAMP-dependent mechanisms. Rodent models have explored VIP’s expression in pulmonary neuroendocrine cells and airway innervation patterns, contributing to researchers’ understanding of non-adrenergic, non-cholinergic (NANC) neurotransmission in the lung.
Gastrointestinal Research
VIP was first isolated from gastrointestinal tissue, and GI biology remains one of its most active preclinical research areas. Studies have examined VIP’s roles in regulating intestinal secretion, smooth muscle relaxation, and enteric nervous system signaling in animal models. Research using isolated intestinal preparations has characterized VIP-mediated chloride secretion through VPAC1 receptor activation of CFTR channels in intestinal epithelial cells — findings that have been used to model VIP’s involvement in normal secretomotor physiology.
This area intersects with ongoing BPC-157 gastrointestinal research, which has explored cytoprotective and motility-related mechanisms in overlapping GI tissue models, providing complementary perspectives on peptide biology at mucosal surfaces.
Explore VIP 10MG research material →
VIP and Neuroprotection Research
A growing body of preclinical literature has examined VIP’s potential neuroprotective properties in cell culture and rodent model systems. In vitro studies have investigated VIP’s effects on neuronal survival following excitotoxic insult, with some research suggesting that VPAC receptor activation may promote expression of neurotrophic factors including BDNF and PACAP-related peptides in neuronal cultures. Rodent studies have employed hippocampal slice preparations and cortical neuron cultures to examine VIP’s interactions with oxidative stress pathways.
These findings have positioned VIP alongside other neuropeptides of research interest, such as those examined in Dihexa cognitive biology research, where synthetic peptides have been explored for their interactions with neurotrophic signaling systems in preclinical models. The mechanistic parallels — particularly around BDNF pathway interactions — make VIP a notable comparison point for researchers working across neuropeptide research programs.
VIP Peptide Analogs in Research
The natural VIP sequence presents certain research challenges due to its enzymatic lability and short half-life in biological matrices. This has driven significant research interest in the development of VIP analogs with modified structures designed to improve stability or receptor selectivity. Preclinical studies have examined several classes of VIP analogs, including:
- C-terminal truncated analogs: Studies have explored minimum active sequence requirements, with research suggesting that the C-terminal region of VIP contributes to receptor binding affinity at both VPAC1 and VPAC2.
- Cyclized analogs: Constraining VIP’s helical conformation through cyclization has been investigated as a strategy for improving receptor selectivity in preclinical binding studies.
- PEGylated derivatives: Research has explored covalent PEG attachment to VIP sequences as a method for extending apparent half-life in plasma stability assays, a common strategy in peptide research tool development.
- Hybrid peptides: PACAP/VIP chimeric sequences have been employed in preclinical studies to dissect the structural determinants of VPAC1 versus VPAC2 selectivity.
The development of these analogs has paralleled similar structural optimization work seen across peptide research, including the DAC modification research explored with CJC-1295, where structural modifications to endogenous peptides have been systematically studied for their effects on receptor engagement and stability profiles.
Laboratory Handling and Research Considerations for VIP
Researchers working with VIP peptide in laboratory settings should be aware of several handling considerations that affect experimental reproducibility. VIP is susceptible to aggregation at elevated concentrations and is subject to proteolytic degradation by neutral endopeptidase 24.11 (neprilysin) and dipeptidyl peptidase IV (DPP-IV) in biological matrices. Standard laboratory protocols recommend:
- Storage of lyophilized VIP at -20°C or below in sealed, desiccated conditions
- Reconstitution using sterile, appropriate buffer solutions — researchers may refer to the bacteriostatic water reconstitution research guide for general reconstitution considerations applicable across peptide research contexts
- Minimizing freeze-thaw cycles through preparation of small working aliquots
- Working at 4°C or on ice during active experimental preparation
- Using carrier proteins such as BSA at low concentrations to reduce surface adsorption losses in dilute solutions
Pfizer Hospira Bacteriostatic Water for peptide reconstitution →
Where These Fit in Your Research Library
Researchers exploring VIP peptide biology may also find the following materials relevant to complementary research programs:
- VIP 10MG — primary research material →
- semax-20mg/”>Selank & Semax 20MG — neuromodulatory peptide research →
- Pinealon 10MG — circadian and neuropeptide research →
Browse the complete research peptide catalog at SourcePeptides.co for the full range of available laboratory research materials.
Final Takeaway: VIP Peptide as a Preclinical Research Subject
Vasoactive intestinal peptide occupies a unique position in peptide research due to its multi-system expression, dual VPAC receptor pharmacology, and involvement in neuroimmune, circadian, pulmonary, and gastrointestinal biology. Preclinical research published through 2026 continues to expand the understanding of how VIP receptor signaling interfaces with broader physiological regulation systems in rodent and in vitro models. Its structural challenges — including proteolytic lability and concentration-dependent aggregation — make it both a technically demanding and scientifically rewarding subject for laboratory investigation.
As researchers continue to develop stabilized analogs and more selective pharmacological tools, VIP remains a foundational subject for scientists investigating neuropeptide signaling, GPCR biology, and neuroimmune crosstalk in preclinical research contexts.
Sources & Further Reading
- Harmar AJ et al. — “The VPAC2 receptor is essential for circadian function in the mouse suprachiasmatic nuclei” — Cell (2002)
- Delgado M, Ganea D — “Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions” — Cellular and Molecular Life Sciences (2008)
- PubMed Search — Vasoactive Intestinal Peptide VPAC Receptor Research Literature
- Vaudry D et al. — “Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions” — Pharmacological Reviews (2009)
- NIH StatPearls — Vasoactive Intestinal Peptide (VIP) Biology Reference
